MBM Future Health

MBM Future Health, Access to Innovative Medicines MBM Future Health offers strategic advice for international stakeholders on access to novel medicines. Public Health and evidence-based decision-making have been the centre of my work for 20 years, almost 10 years at Germany’s top health policy body, the G-BA. My particular focus for 15 years has been on rare diseases, including cell and gene therapies. A challenge I currently tackle is the use of real-world data, balancing opportunities and risks of AI. I am pleased to offer you strategic regulatory advice to ensure that patients get access to the best possible new medicines. For rare diseases and other neglected diseases. Overall, for the best possible treatments in challenging indications. Let's work together!